$69.83
Live
0.93%
Downside
Day's Volatility :1.44%
Upside
0.51%
15.61%
Downside
52 Weeks Volatility :38.69%
Upside
27.35%
Period | Edwards Lifesciences Corp. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -20.14% | 3.6% | 6.5% |
6 Months | -19.19% | 10.2% | 18.1% |
1 Year | 1.77% | 19.6% | 38.8% |
3 Years | -39.29% | 16.8% | 28.9% |
Market Capitalization | 42.3B |
Book Value | $12.35 |
Earnings Per Share (EPS) | 2.54 |
PE Ratio | 27.67 |
PEG Ratio | 3.65 |
Wall Street Target Price | 75.26 |
Profit Margin | 23.74% |
Operating Margin TTM | 27.22% |
Return On Assets TTM | 12.28% |
Return On Equity TTM | 22.02% |
Revenue TTM | 6.2B |
Revenue Per Share TTM | 10.27 |
Quarterly Revenue Growth YOY | 7.000000000000001% |
Gross Profit TTM | 4.3B |
EBITDA | 2.0B |
Diluted Eps TTM | 2.54 |
Quarterly Earnings Growth YOY | 0.21 |
EPS Estimate Current Year | 2.6 |
EPS Estimate Next Year | 2.61 |
EPS Estimate Current Quarter | 0.69 |
EPS Estimate Next Quarter | 0.69 |
What analysts predicted
Upside of 7.78%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | ↑ 8.37% |
Net Income | 722.2M | ↑ 16.09% |
Net Profit Margin | 19.4% | ↑ 1.29% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.3B | ↑ 16.79% |
Net Income | 1.0B | ↑ 44.96% |
Net Profit Margin | 24.08% | ↑ 4.68% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 4.4B | ↑ 0.88% |
Net Income | 823.4M | ↓ 21.35% |
Net Profit Margin | 18.77% | ↓ 5.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 5.2B | ↑ 19.29% |
Net Income | 1.5B | ↑ 82.55% |
Net Profit Margin | 28.73% | ↑ 9.96% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 5.4B | ↑ 2.86% |
Net Income | 1.5B | ↑ 1.25% |
Net Profit Margin | 28.28% | ↓ 0.45% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 6.0B | ↑ 11.56% |
Net Income | 1.4B | ↓ 7.85% |
Net Profit Margin | 23.35% | ↓ 4.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↑ 8.25% |
Net Income | 340.5M | ↓ 14.53% |
Net Profit Margin | 23.33% | ↓ 6.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↑ 4.84% |
Net Income | 307.1M | ↓ 9.81% |
Net Profit Margin | 20.07% | ↓ 3.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↓ 3.22% |
Net Income | 384.9M | ↑ 25.33% |
Net Profit Margin | 25.99% | ↑ 5.92% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↑ 3.59% |
Net Income | 369.9M | ↓ 3.9% |
Net Profit Margin | 24.11% | ↓ 1.88% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.6B | ↑ 4.18% |
Net Income | 351.9M | ↓ 4.87% |
Net Profit Margin | 22.02% | ↓ 2.09% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.4B | ↓ 13.28% |
Net Income | 366.3M | ↑ 4.09% |
Net Profit Margin | 26.43% | ↑ 4.41% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 5.3B | ↓ 6.54% |
Total Liabilities | 2.2B | ↓ 19.19% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↑ 21.87% |
Total Liabilities | 2.3B | ↑ 7.17% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 7.2B | ↑ 11.54% |
Total Liabilities | 2.7B | ↑ 13.8% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 8.5B | ↑ 17.49% |
Total Liabilities | 2.7B | ↑ 0.15% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 8.3B | ↓ 2.47% |
Total Liabilities | 2.5B | ↓ 6.78% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 9.4B | ↑ 12.91% |
Total Liabilities | 2.6B | ↑ 6.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.7B | ↑ 4.33% |
Total Liabilities | 2.6B | ↑ 4.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.0B | ↑ 4.08% |
Total Liabilities | 2.6B | ↓ 1.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.4B | ↑ 4.07% |
Total Liabilities | 2.6B | ↑ 3.37% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.4B | ↓ 0.08% |
Total Liabilities | 2.6B | ↑ 0.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 9.7B | ↑ 3.98% |
Total Liabilities | 2.5B | ↓ 3.55% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 10.1B | ↑ 3.73% |
Total Liabilities | 2.6B | ↑ 1.76% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 926.8M | ↓ 7.38% |
Investing Cash Flow | 76.7M | ↓ 111.85% |
Financing Cash Flow | -1.1B | ↑ 132.71% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↑ 27.26% |
Investing Cash Flow | -595.8M | ↓ 876.79% |
Financing Cash Flow | -115.6M | ↓ 89.5% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↓ 10.61% |
Investing Cash Flow | -531.1M | ↓ 10.86% |
Financing Cash Flow | -486.9M | ↑ 321.19% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↑ 64.29% |
Investing Cash Flow | -1.7B | ↑ 224.33% |
Financing Cash Flow | -356.3M | ↓ 26.82% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↓ 29.67% |
Investing Cash Flow | 252.3M | ↓ 114.65% |
Financing Cash Flow | -1.6B | ↑ 344.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 314.1M | ↑ 11.07% |
Investing Cash Flow | 500.0K | ↓ 99.8% |
Financing Cash Flow | -206.6M | ↓ 75.36% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 33.6M | ↓ 89.3% |
Investing Cash Flow | 70.2M | ↑ 13940.0% |
Financing Cash Flow | 52.1M | ↓ 125.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 411.5M | ↑ 1124.7% |
Investing Cash Flow | 159.7M | ↑ 127.49% |
Financing Cash Flow | -143.3M | ↓ 375.05% |
Sell
Neutral
Buy
Edwards Lifesciences Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Edwards Lifesciences Corp.
Revenue is down for the last 2 quarters, 1.59B → 1.38B (in $), with an average decrease of 13.3% per quarter
Netprofit is up for the last 2 quarters, 351.9M → 366.3M (in $), with an average increase of 3.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 74.9%
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 135.6%
Vanguard Group Inc
BlackRock Inc
State Street Corp
AllianceBernstein L.P.
Bank of New York Mellon Corp
Wellington Management Company LLP
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
Organization | Edwards Lifesciences Corp. |
Employees | 19800 |
CEO | Mr. Bernard J. Zovighian |
Industry | Health Technology |
Pnc Financial Services Group, Inc.
$69.83
-0.63%
Mid-cap Value Etf Vanguard
$69.83
-0.63%
Unilever Plc
$69.83
-0.63%
Sirius Xm Holdings Inc.
$69.83
-0.63%
Airbnb
$69.83
-0.63%
Caterpillar Inc.
$69.83
-0.63%
Ishares Core Dividend Growth Etf
$69.83
-0.63%
Tenet Healthcare Corp.
$69.83
-0.63%
W.r. Berkley Corporation
$69.83
-0.63%